D Lavanchy - Journal of Viral hepatitis, 2004 - medscape.com World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204
(Revised October 2000). WHO Web site. 2000. http://who.int/inf-fs/en/fact204.
html. ... Liaw YF, Leung NW, Chang TT et al. Effects of extended ... Cited by 537 - Related articles - BL Direct - All 7 versions
WGE Cooksley, T Piratvisuth, SD Lee, V … - Journal of viral hepatitis, 2003 - medscape.com Current therapies for chronic hepatitis B (CHB) have a number of limitations,
and better treatment options are needed. Peginterferon -2a (40 kDa) is superior
to conventional interferon -2a in the treatment of chronic hepatitis C. ... Cited by 340 - Related articles - BL Direct - All 7 versions
- ►infectshma.org.cn [PDF] MM Jonas, DA Kelley, J Mizerski, IB Badia, … - The New England journal of medicine, 2002 - nejm.highwire.org 1706 · N Engl J Med, Vol. 346, No. 22 · May 30, 2002 · www.nejm.org ...
CLINICAL TRIAL OF LAMIVUDINE IN CHILDREN WITH CHRONIC HEPATITIS B ... M AUREEN
M. J ONAS , MD, D EIRDRE A. K ELLEY , MD, J ACEK M IZERSKI , MD, I SABEL B. ... Cited by 220 - Related articles - BL Direct - All 13 versions
RJ Colonno, R Rose, CJ Baldick, S Levine, K … - Studies - file.yynet.cn ETV-treated patients exhibited virologic rebound by Week 96. Three ETV rebounds
were attributable to LVDr virus present at baseline, with one having a S202G ETV
resistance (ETVr) substitution emerge at Week 48. None of the other ... Cited by 170 - Related articles - View as HTML - BL Direct - All 8 versions
K Das, X Xiong, H Yang, CE Westland, CS … - The Journal of Virology, 2001 - jvi.asm.org.p.angrylapdog.com Success in treating hepatitis B virus (HBV) infection with nucleoside analog
drugs like lamivudine is limited by the emergence of drug-resistant viral
strains upon prolonged therapy. The predominant lamivudine resistance ... Cited by 146 - Related articles - BL Direct - All 7 versions
GV Papatheodoridis, SJ Hadziyannis - Journal of Viral Hepatitis, 2001 - interscience.wiley.com Chronic hepatitis due to pre-core hepatitis B virus (HBV) mutants presents as
hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). HBeAg-negative
CHB represents a late phase in the natural course of chronic HBV infection ... Cited by 129 - Related articles - BL Direct - All 3 versions
WE Delaney… - Antiviral chemistry & chemotherapy, 2001 - ncbi.nlm.nih.gov Despite the existence of vaccines, chronic hepatitis B virus (HBV) infection
remains a major health problem worldwide. Interferon therapy successfully
controls infection in only a small percentage of chronically infected ... Cited by 81 - Related articles - BL Direct - All 6 versions
EE Mast, JW Ward - Vaccines. 4th ed. Orlando, FL: WB Saunders Co, 2003 - thelancetglobalhealthnetwork.com Viral hepatitis has been recognized as a clinical entity since antiquity, but
the diversity of viruses causing hepatitis has only recently been recognized. Of
the five viruses that are known to cause hepatitis in humans, hepatitis B ... Cited by 70 - Related articles - View as HTML - All 2 versions
HE Blum - 世界胃肠病学杂志: 英文版, 2005 - wjgnet.com Hepatocellular carcinoma (HCC) is one of the most common malignant tumors
worldwide. The major etiologies and risk factors for the development of HCC are
well defined and some of the multiple steps involved in ... Cited by 69 - Related articles - Cached - BL Direct - All 10 versions
